Institutions		activities	Rese	When	Tot
Academia	Industry		arche r		mths
Centre hoopitalier universitaire vaudoils		Purification of AAV1 and AAV9 vectors	ER19	M16-17	2
UMB =		Methods development & SOP* for the AAV9	ER17	M16-17	2
LUND UNIVERSITY	bet	Methods development & SOP* for the LVs	ER16	M16-19	4
	<u> </u>	 CAV2-tet in 3D neuronal cultures Methods development & SOP* of CAV2-tet 	ER2 ER3	M16-17 M34-41	2 8
		■ Cloning of CAV-tetON & SOP* CAV	ER8 ER9 ER10	M11-14 M15-22 M19-22	4 8 4
(Universidad	, RI ==	3D cultures with AAV with cell-specific tet	ER4 ESR3	M11-12 M16-17	2 2
de Navarra		Purification process of AAVs & purity check	ER12	M35-36	2
LUND	e Biología vlat e Tecno	Methods development & SOP of LVs	ER13	M27-28	2
UMB (=	ogica	■ Methods development & SOP* of CAV & AAV	ER14	M29-32	4
SAPIENZA UNIVERSITÀ DI ROMA	<u> </u>	CAV2 on 3D culturesqPCR of toxic response	ER11 ER15	M10-11 M37-38	2 2
am C	3	 Immunogenicity of new rtTA mutants Immunogenicity of neuron-specific AAV-tetON 	ER1 ER5	M10-11, 23-24 M25-26	4 2
Universidad de Navarra		Standardization of HLA hum-mouse models HLA respectativities are still to HLA respectativities by the partners Impube defined by the partners	ESR2 ER6	M29-30, 47-48 M27-30	4 4
	_ > >	Immube defined by the particular to the control of	ESR1	M39-40	2
		<i>In vivo</i> immunogenicity of candidate epitopic peptides	ER7	M30-31	2
UMB (=	S	Immunogenicity of AAV9	ESR4	M36-37	2
SAPIENZA UNIVERSITÀ DI ROMA	>	Analysis of cell-vector interaction on primary cells and 3D cell cultures	ER18	M20-21	2

^{*} Standard Operation Procedure